Research Analysts Offer Predictions for ALUR FY2025 Earnings

Allurion Technologies Inc. (NYSE:ALUR) – Equities research analysts at Roth Capital raised their FY2025 earnings per share estimates for Allurion Technologies in a note issued to investors on Wednesday, May 14th. Roth Capital analyst J. Wittes now expects that the company will post earnings per share of ($0.13) for the year, up from their previous estimate of ($2.57). The consensus estimate for Allurion Technologies’ current full-year earnings is ($9.96) per share. Roth Capital also issued estimates for Allurion Technologies’ Q4 2025 earnings at ($0.33) EPS and FY2026 earnings at $2.06 EPS.

Several other equities research analysts have also issued reports on ALUR. Chardan Capital reaffirmed a “neutral” rating and set a $2.50 price target on shares of Allurion Technologies in a research note on Thursday, March 27th. Roth Mkm reaffirmed a “buy” rating and set a $16.00 price target on shares of Allurion Technologies in a research note on Friday, March 21st.

Allurion Technologies Stock Up 10.5%

Shares of ALUR stock opened at $3.17 on Monday. The business has a 50-day moving average price of $2.62 and a two-hundred day moving average price of $5.97. Allurion Technologies has a 12-month low of $2.15 and a 12-month high of $88.75. The firm has a market cap of $23.64 million, a P/E ratio of -0.26 and a beta of -0.58.

Allurion Technologies (NYSE:ALUR) last posted its quarterly earnings data on Wednesday, May 14th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.53) by $1.96. The business had revenue of $5.58 million for the quarter, compared to the consensus estimate of $5.50 million.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Allurion Technologies stock. XTX Topco Ltd purchased a new stake in shares of Allurion Technologies Inc. (NYSE:ALUR) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 13,037 shares of the company’s stock, valued at approximately $42,000. XTX Topco Ltd owned 0.27% of Allurion Technologies at the end of the most recent reporting period. Institutional investors and hedge funds own 21.39% of the company’s stock.

Insider Transactions at Allurion Technologies

In related news, CEO Shantanu Gaur acquired 8,000 shares of the firm’s stock in a transaction dated Friday, March 28th. The shares were purchased at an average price of $3.35 per share, for a total transaction of $26,800.00. Following the completion of the acquisition, the chief executive officer now owns 8,000 shares in the company, valued at approximately $26,800. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Company insiders own 9.60% of the company’s stock.

Allurion Technologies Company Profile

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.